Properties (38)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
anticoagulant
|
| gptkbp:activeDuring |
rivaroxaban
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:brand |
gptkb:Xarelto
|
| gptkbp:chemicalFormula |
C19H18ClN3O5S
|
| gptkbp:clinicalTrials |
Phase III
|
| gptkbp:commonName |
rivaroxaban
|
| gptkbp:contraindication |
active bleeding
severe renal impairment hypersensitivity to rivaroxaban |
| gptkbp:dosageForm |
tablet
|
| gptkbp:drugInterdiction |
NSAIDs
anticoagulants antiplatelet agents |
| gptkbp:gestationPeriod |
C
|
| https://www.w3.org/2000/01/rdf-schema#label |
Xarelto
|
| gptkbp:lastProduced |
2011
|
| gptkbp:mandates |
atrial fibrillation
venous thromboembolism post-surgical thromboprophylaxis |
| gptkbp:manufacturer |
gptkb:Johnson_&_Johnson
gptkb:Bayer_AG |
| gptkbp:name |
Essential Medicines
|
| gptkbp:numberOfStudents |
5 to 9 hours
|
| gptkbp:nutritionalValue |
liver
|
| gptkbp:operates_in |
B01AF06
|
| gptkbp:route |
oral
|
| gptkbp:sideEffect |
anemia
nausea bleeding liver enzyme abnormalities |
| gptkbp:skills |
10 mg
15 mg 20 mg |
| gptkbp:usedFor |
preventing blood clots
reducing the risk of stroke treating deep vein thrombosis treating pulmonary embolism |